» Articles » PMID: 12098063

Lorazepam for Seizure Prophylaxis During High-dose Busulfan Administration

Overview
Specialty General Surgery
Date 2002 Jul 5
PMID 12098063
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Seizure is a recognized complication of high-dose busulfan (BU) therapy and phenytoin (DPH) is widely used as prophylaxis. A number of adverse effects have been associated with DPH and it may also interfere with BU metabolism. We used lorazepam (median dose 0.022 mg/kg) i.v. or p.o. before each dose and for 24 h after the last dose of BU as seizure prophylaxis to 29 children undergoing hematopoietic stem cell transplantation. The regimen was well tolerated and drowsiness was the only significant side-effect. Twelve patients were able to receive the entire prophylaxis by mouth. No seizure developed during and within 48 h of BU. Concomitant pharmacokinetic studies showed no alternation of the absorption and clearance of BU during lorazepam administration. Lorazepam can be used as an alternative for seizure prophylaxis during high-dose BU treatment.

Citing Articles

Prospective observational study of oral clonazepam to prevent high-dose busulfan-induced seizures in adult patients.

Diaz-Carrasco M, Sanchez-Salinas A, Fernandez-Avila J, Olmos-Jimenez R, Espanol-Morales I, Espuny-Miro A J Egypt Natl Canc Inst. 2025; 37(1):4.

PMID: 39894848 DOI: 10.1186/s43046-025-00257-3.


Epileptic Seizures After Allogeneic Hematopoietic Stem Cell Transplantation.

Wang Z, Zhao M, Gao S Front Neurol. 2021; 12:675756.

PMID: 34335446 PMC: 8322618. DOI: 10.3389/fneur.2021.675756.


Comparison of valproate and levetiracetam for the prevention of busulfan-induced seizures in hematopoietic stem cell transplantation.

Nakashima T, Tanaka T, Koido K, Nishibuchi Y, Hashimoto H, Ito A Int J Hematol. 2019; 109(6):694-699.

PMID: 30915718 DOI: 10.1007/s12185-019-02637-7.


Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review.

Myers A, Kawedia J, Champlin R, Kramer M, Nieto Y, Ghose R Expert Opin Drug Metab Toxicol. 2017; 13(9):901-923.

PMID: 28766962 PMC: 5584057. DOI: 10.1080/17425255.2017.1360277.


Minimal incidence of neurotoxicity without prophylaxis during busulfan-based conditioning regimen in patients undergoing stem cell transplantation.

Leon-Rodriguez E, Rivera-Franco M Int J Hematol. 2016; 104(6):644-646.

PMID: 27722893 DOI: 10.1007/s12185-016-2098-8.